15th Oct 2015 05:36
LONDON (Alliance News) - Switzerland's Basilea Pharmaceuticals Ltd on Thursday morning said it has signed an exclusive distribution and supply deal with London-listed Hikma Pharmaceuticals PLC for Basilea's Zevtera antibiotic.
Under the terms of the agreement, which will cover the Middle East and North Africa region, Hikma's Hikma Pharmaceuticals LLC unit will hold the rights to register, distribute and market Zevtera across the region.
The financial terms of the agreement between the two were not disclosed.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Hikma Pharmaceuticals